Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.04 USD
Change Today +0.07 / 0.41%
Volume 18.1K
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

psychemedics corp (PMD) Key Developments

Psychemedics Corp. Reports Unaudited Earnings Results for Fourth Quarter and Full Year Ended December 31, 2014

Psychemedics Corp. reported unaudited earnings results for fourth quarter and full year ended December 31, 2014. The company's revenue for the fourth quarter ended December 31, 2014 was $6.8 million versus $6.5 million for the quarter ended December 31, 2013, an increase of 4%. Net income and comprehensive income was $676,000 or $0.13 per diluted share, versus $867,939 or $0.16 per diluted share, for the comparable period last year, a decrease of 22%. Operating income was $957,670 against $1,033,155 a year ago. Net income before provision for income taxes was $930,251 against $1,033,435 a year ago. The company's revenue for the year ended December 31, 2014 was $29.2 million versus $26.9 million for the twelve months ended December 31, 2013, an increase of 9%. Net income and comprehensive income was $3.2 million or $0.60 per diluted share, versus $3.8 million or $0.72 per diluted share, for the comparable period last year, a decrease of 16%. Operating income was $4,689,641 against $5,706,365 a year ago. Net income before provision for income taxes was $4,633,065 against $5,798,638 a year ago.

Psychemedics Corporation Declares Quarterly Dividend, Payable on March 6, 2015

Psychemedics Corporation announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 23, 2015 to be paid on March 6, 2015.

Psychemedics Corp. Presents at 17th Annual Needham Growth Conference, Jan-15-2015 08:40 AM

Psychemedics Corp. Presents at 17th Annual Needham Growth Conference, Jan-15-2015 08:40 AM. Venue: New York Palace Hotel, 455 Madison Avenue, New York, New York, United States.

Psychemedics Announces Quarterly Dividend, Payable on November 20, 2014; Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Psychemedics Corp. also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of November 10, 2014 to be paid on November 20, 2014. The company reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenues of $7,704,047 compared to $7,055,202 a year ago. Operating income was $1,244,211 compared to $1,739,299 a year ago. Net income before provision for income taxes was $1,210,270 compared to $1,739,579 a year ago. Net income and comprehensive income was $916,900 or $0.17 basic and diluted per share compared to $1,052,000 or $0.20 basic and diluted per share a year ago. For the nine months, the company reported revenues of $22,443,005 compared to $20,386,381 a year ago. Operating income was $3,731,971 compared to $4,673,210 a year ago. Net income before provision for income taxes was $3,702,814 compared to $4,765,203 a year ago. Net income and comprehensive income was $2,529,978 or $0.47 per basic and diluted share compared to $2,937,271 or $0.55 per basic and diluted share a year ago.

Psychemedics Corp. Announces Quarterly Dividend, Payable on August 18, 2014; Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Psychemedics Corp. announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 7, 2014 to be paid on August 18, 2014. The company reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's revenue was $7.7 million versus $6.9 million for the quarter ended June 30, 2013, an increase of 12%. Net income was $0.857 million or $0.16 per diluted share, versus $1.1 million or $0.20 per diluted share, for the comparable period last year, a decrease of 19%. Operating income was $1.319 million compared with $1.731 million for the same period last year. Net income before provision for income taxes was $1.322 million compared with $1.732 million for the same period last year. For the six months, the company's revenue was $14.7 million versus $13.3 million for the six months ended June 30, 2013, an increase of 11%. Net income was $1.6 million or $0.30 per diluted share, versus $1.9 million or $0.36 per diluted share, for the comparable period last year, a decrease of 14%. Operating income was $2.487 million compared with $2.933 million for the same period last year. Net income before provision for income taxes was $2.492 million compared with $3.025 million for the same period last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PMD:US $17.04 USD +0.07

PMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $24.00 USD -0.04
Enzo Biochem Inc $2.70 USD +0.04
Genomic Health Inc $30.38 USD -0.84
NeoGenomics Inc $4.84 USD +0.02
Response Genetics Inc $0.34 USD +0.01
View Industry Companies
 

Industry Analysis

PMD

Industry Average

Valuation PMD Industry Range
Price/Earnings 28.6x
Price/Sales 3.1x
Price/Book 7.1x
Price/Cash Flow 28.6x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PSYCHEMEDICS CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.